More significantly, studies have shown that EGFR is dysregulated in many solid tumors, and PI3K-AKT signaling can be used as a downstream regulatory pathway for EGFR to mediate the occurrence and progression of disease, as confirmed in many cancers [40, 41]. The gene discussed is AKT1; the disease is cancer.